产品名称 | NebuSelect™ Recombinant Biotinylated Human EGFRVIII, Avi-His-tag |
---|---|
目录号 | NBL-241031 |
别名 | EGFRVIII; ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2 |
外观 | see COA |
分子量 | Leu25-Ser378 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | NP_001333870.1 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-241031-100ug | 100ug | Inquire | Inquire | |
NBL-241031-1mg | 1mg | Inquire | Inquire | |
NBL-241031-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Biotinylated Human EGFRVIII, Avi-His-tag
Catalog#:
NBL-241031
Description:
NebuSelect™ Recombinant Biotinylated Human EGFRVIII, Avi-His-tag(Cat#NBL-241031) is expressed in HEK293 with His tag and Avi tag at the C-Terminus.It contains Leu25-Ser378.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 41.6 kDa. Due to glycosylation, the protein migrates to 60-78 kDa based on Bis-Tris PAGE result.
Target Name:
EGFRVIII; ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2
Target Information:
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.
Amino Acid Sequence:
Leu25-Ser378
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.